2024
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencing
2020
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Yan G, Wang S, Gao Y, Brandhofer M, Megens RTA, Hoffmann A, Pauli J, Asare Y, Gerra S, Bourilhon P, Leng L, Eckstein HH, Kempf WE, Pelisek J, Gokce O, Maegdefessel L, Bucala R, Dichgans M, Weber C, Kapurniotu A, Bernhagen J. Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. Nature Communications 2020, 11: 5981. PMID: 33239628, PMCID: PMC7689490, DOI: 10.1038/s41467-020-19764-z.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsAntigens, CDAtherosclerosisBinding SitesCarotid Artery, CommonChemokine CXCL12Crystallography, X-RayDisease Models, AnimalDrug DesignDrug Evaluation, PreclinicalEndarterectomy, CarotidFemaleHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMiceMice, Knockout, ApoEMiddle AgedPeptide FragmentsReceptors, CXCR4SialyltransferasesSignal TransductionConceptsMacrophage migration inhibitory factorCXC motif chemokine receptor 4Chemokine receptorsChemokine/receptor axisCXCR4/CXCL12 interactionHuman carotid endarterectomy specimensMigration inhibitory factorChemokine receptor 4MIF/CD74Carotid endarterectomy specimensAtherogenic inflammationCXCL12 interactionReceptor axisReceptor 4MIF inhibitorsReceptor-based strategiesAtherosclerotic plaquesAtherosclerosisAtypical chemokineLeukocyte adhesionCell activityProtective pathwaysInflammationChemokinesPlaques
2000
Expression of macrophage migration inhibitory factor in human glomerulonephritis
Lan H, Yang N, Nikolic-Paterson D, Yu X, Mu W, Isbel N, Metz C, Bucala R, Atkins R. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney International 2000, 57: 499-509. PMID: 10652026, DOI: 10.1046/j.1523-1755.2000.00869.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiopsyCohort StudiesEpithelial CellsFemaleGene ExpressionGlomerulonephritis, MembranoproliferativeGlomerulonephritis, MembranousHumansIn Situ HybridizationKidney GlomerulusMacrophage Migration-Inhibitory FactorsMacrophagesMaleMiddle AgedReference ValuesRNA, MessengerT-LymphocytesConceptsMacrophage migration inhibitory factorMIF expressionMigration inhibitory factorFocal segmental glomerulosclerosisHuman glomerulonephritisProliferative formsMIF mRNAPathogenic roleExperimental glomerulonephritisInhibitory factorProgressive formRenal MIF expressionRenal function impairmentT cell accumulationT-cell infiltratesEpithelial cellsMinimal change diseaseFocal segmental lesionsGlomerular endothelial cellsTubular epithelial cellsNormal human kidneyAttractive therapeutic targetCreatinine clearanceGlomerular epithelial cellsLupus nephritisProtection from septic shock by neutralization of macrophage migration inhibitory factor
Calandra T, Echtenacher B, Roy D, Pugin J, Metz C, Hültner L, Heumann D, Männel D, Bucala R, Glauser M. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine 2000, 6: 164-170. PMID: 10655104, DOI: 10.1038/72262.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorSeptic shockMigration inhibitory factorLethal peritonitisSevere sepsisMIF antibodyRecombinant macrophage migration inhibitory factorAnti-tumor necrosis factorInhibitory factorTNFα knockout micePathogenesis of sepsisPlasma of patientsNew therapeutic targetsBacterial peritonitisIll patientsInvestigational therapiesCecal ligationNecrosis factorNormal micePivotal cytokineSystemic circulationKnockout miceTherapeutic targetSepsisPeritonitis
1999
Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids
Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth S, Bucala R, Morand E. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis & Rheumatism 1999, 42: 1601-1608. PMID: 10446857, DOI: 10.1002/1529-0131(199908)42:8<1601::aid-anr6>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAgedArthritis, RheumatoidCells, CulturedCytokinesGlucocorticoidsHumansImmunohistochemistryInterferon-gammaLymphocyte ActivationMacrophage Migration-Inhibitory FactorsMacrophagesMonocytesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSynovial MembraneT-LymphocytesTumor Necrosis Factor-alphaConceptsMacrophage migration inhibitory factorFibroblast-like synoviocytesRA fibroblast-like synoviocytesEnzyme-linked immunosorbent assayRheumatoid arthritisMigration inhibitory factorTNFalpha releaseExpression of MIFIntracellular macrophage migration inhibitory factorInhibitory factorCultured RA fibroblast-like synoviocytesCytokine macrophage migration inhibitory factorCultured fibroblast-like synoviocytesTumor necrosis factor-alpha synthesisHuman RA synoviumRA synovial tissueNecrosis factor-alpha synthesisHuman autoimmune diseasesPotential therapeutic targetTranscription-polymerase chain reactionMessenger RNA expressionT cell activationMIF expressionRA patientsRA synovium
1998
Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers
Nicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R. Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. Molecular Medicine 1998, 4: 594-601. PMID: 9848076, PMCID: PMC2230315, DOI: 10.1007/bf03401759.Peer-Reviewed Original ResearchConceptsNondiabetic smokersTissues of smokersCoronary arteryGlycation endproductsSingle greatest preventable causeGreatest preventable causeEnd-organ complicationsAnti-AGE antibodyConsequence of diabetesAdvanced glycation endproductsRenal insufficiencyCigarette smokersPreventable causeSmokersCigarette smokeHigh levelsCausal associationNonsmokersDiabetesMainstream cigarette smokeBlood vesselsAgeExtracellular matrix proteinsArteryLens fiber cells
1997
Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs
Stitt A, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li Y, Bucala R, Vlassara H. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. Molecular Medicine 1997, 3: 617-627. PMID: 9323713, PMCID: PMC2230092, DOI: 10.1007/bf03401819.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgingApolipoproteins BArteriosclerosisCarotid ArteriesCollagenEndothelium, VascularEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunohistochemistryMacrophagesMaleMicroscopy, FluorescenceMiddle AgedReceptor for Advanced Glycation End ProductsReceptors, ImmunologicRegression AnalysisConceptsSmooth muscle cellsAGE-specific receptorsMononuclear cellsAtherosclerotic vascular diseaseOcclusive atherosclerotic diseaseDevelopment of hyperlipidemiaLipid-laden macrophagesYoung healthy personsEarly-stage lesionsCardiac bypass patientsAGE-R1Nondiabetic patientsAsymptomatic patientsAsymptomatic personsBypass patientsNormolipidemic patientsAtherosclerotic diseaseDistribution of ageVascular diseaseInflammatory responseLate-stage plaquesAtheromatous lesionsEarly lesionsFatty streaksNondiabetic etiologyOrally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6474-6479. PMID: 9177242, PMCID: PMC21074, DOI: 10.1073/pnas.94.12.6474.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsDietary advanced glycation endproductsEndogenous advanced glycation endproductsDiabetes mellitusKidney diseaseRenal excretionRenal vascular injuryDiabetic nephropathy patientsSerum AGE levelsDegree of albuminuriaNondiabetic kidney diseaseEnvironmental risk factorsAGE immunoreactivityRenal complicationsCreatinine clearanceDiabetic nephropathyNephropathy patientsRenal failureDiabetic patientsRisk factorsFood intakeHealthy subjectsGlycation endproductsDietary restrictionCL diet
1996
Glycation and microglial reaction in lesions of Alzheimer's disease
Dickson D, Sinicropi S, Yen S, Ko L, Mattiace L, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiology Of Aging 1996, 17: 733-743. PMID: 8892346, DOI: 10.1016/0197-4580(96)00116-9.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAGE immunoreactivityNeurofibrillary tanglesExtracellular neurofibrillary tanglesAmyloid depositsMicroglial reactionActivation of microgliaIntracellular neurofibrillary tanglesAlzheimer's disease brainPattern of immunoreactivityGlycation end productsTriple immunostainingDisease brainSenile plaquesDiffuse amyloidAlzheimer's diseaseImmunoreactivityCryostat sectionsDouble labelingAntibodiesMicrogliaLesionsPolyclonal antibodiesDiseaseGlycation
1995
Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy
Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsSevere diffuse lesionsAnti-AGE antibodyComplications of diabetesInner elastic layerRenal complicationsDiabetic nephropathyAGE antibodyDiffuse lesionsNondiabetic individualsVascular lesionsPathogenic roleAGE accumulationHyaline depositsImmunohistochemical stainingPositive stainingImmunohistochemical detectionAdvanced glycosylationVascular intimaNormal agingSpecific antibodiesTissue distributionEnd productsAntibodies
1988
Labile T-wave changes caused by respiratory variation in a patient with unstable angina
Bucala R, Loh E, Wang P, Rutherford J. Labile T-wave changes caused by respiratory variation in a patient with unstable angina. International Journal Of Cardiology 1988, 19: 260-262. PMID: 3372087, DOI: 10.1016/0167-5273(88)90087-3.Peer-Reviewed Original Research